MExifine solution 50mg/ml 2ml ampoules, 10pcs

Composition

Active ingredient:

ethylmethylhydroxypyridine succinate-50 mg;

Auxiliary substance-water for injection

Pharmacological action

MExifine belongs to the group of compounds of 3-hydroxypyridine and succinic acid and has antioxidant, antihypoxic, membrane-stabilizing, nootropic, stress-protective, anticonvulsant and anxiolytic effects.

MExifine acts as a free radical inhibitor, inhibits the processes of lipid peroxidation, increases the activity of the antioxidant system of enzymes, restores the structure and functions of membranes that are disturbed in various pathologies, has a modulating effect on membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholine diesterase), ion channels, receptor complexes, including benzodiazepine, GABA, acetylcholine improves the transport of neurotransmitters, synaptic transmission and interconnection of brain structures.

Increases the content of dopamine in the brain. The mechanism of action of mExifine is due to its ability to enhance the compensatory activation of aerobic glycolysis. It reduces the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions, increasing the content of ATP and creatine phosphate; it helps to preserve the structural and functional organization of biomembranes.

MExifine improves brain metabolism and blood supply to the brain, corrects disorders in the regulatory and microcirculatory systems, suppressing the constriction of arterioles and precapillaries; improves the rheological properties of blood, reducing platelet aggregation, stabilizing the membrane structures of blood cells (red blood cells and platelets), preventing hemolysis; improves the activity of the immune system.

MExifine has an antiatherogenic effect, causing regression of atherosclerotic changes in the arteries, reducing the level of cholesterol and low-density lipoproteins, restoring lipid homeostasis.

MExifine increases the efficiency and resistance of the body to the effects of various extreme damaging factors in oxygen-dependent pathological conditions (shock, stress, hypoxia and ischemia, cerebral circulation disorders, physical and mental overload), alcohol intoxication and antipsychotic drugs (neuroleptics).

Indications

• Acute and chronic cerebral circulatory disorders, including ischemic stroke and its consequences;
• dyscirculatory encephalopathy, vegetative-vascular dystonia;
• psychosomatic diseases;
• neurotic and neurosis-like disorders with manifestations of anxiety, fear, emotional tension;
• memory and attention disorders, impaired mental performance; 
• mental and neurological diseases in the elderly, cerebral vascular atherosclerosis; 
• relief of alcohol withdrawal syndrome accompanied by neurosis-like and vegetative-vascular disorders; 
• acute neuroleptic intoxication; 
• acute purulent-inflammatory processes of the abdominal cavity: acute necrotizing pancreatitis, peritonitis (as part of complex therapy).

Use during pregnancy and lactation

Contraindicated

Contraindications

Hypersensitivity to oxymethylethylpyridine succinate and / or pyridoxine, acute liver and kidney function disorders, pregnancy, breast-feeding.

Side effects

Nausea, dry mouth, allergic reactions.

How to take, course of use and dosage

MExifine is administered intramuscularly or intravenously (jet or drip). Doses are selected individually. The duration of treatment and dosage regimen depends on the severity of the patient’s condition and the effectiveness of treatment. Start treatment with a dose of 50-100 mg 1-3 times a day, gradually increasing the dose until a therapeutic effect is obtained. The maximum daily dose should not exceed 800 mg.

With the infusion method of use, the drug should be diluted in saline sodium chloride solution.

Jet mExifine is administered slowly for 5-7 minutes; drip-at a rate of 60 drops per minute.

Acute cerebral circulatory disorders: as part of combination therapy, intravenously drip 200-300 mg in the first 2-4 days, then intramuscularly 100 mg 3 times a day. The course duration is 10-14 days.

Dyscirculatory encephalopathy (decompensation phase): intravenous jet or drip 100 mg 2-3 times a day for 14 days, then intramuscularly 100 mg per day for the next 14 days.

Prevention of dyscirculatory encephalopathy: intramuscularly 100 mg 2 times a day for 10-14 days.

Mild cognitive impairment in elderly patients and anxiety disorders: intramuscularly 100-300 mg per day for 14-30 days.

Alcohol withdrawal syndrome: 100-200 mg intramuscularly 2-3 times a day or intravenously 1-2 times a day for 5-7 days.

Acute neuroleptic intoxication: intravenously 50-300 mg per day for 7-14 days, depending on the severity of the condition.

In neurotic disorders and vegetative-vascular dystonia, the drug is prescribed intramuscularly at a dose of 50-400 mg per day for 14 days.

Form of production

Solution for intravenous and intramuscular use

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

3 years

Active ingredient

Ethylmethylhydroxypyridine Succinate

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection